| Literature DB >> 34635486 |
Xia Bu1, Vikram R Juneja2,3,4, Arlene H Sharpe3,4, Gordon J Freeman5, Carol G Reynolds1, Kathleen M Mahoney1, Melissa T Bu1, Kathleen A McGuire3,4, Seth Maleri3,4, Ping Hua1, Baogong Zhu1, Sarah R Klein1, Edward A Greenfield1, Philippe Armand1, Jerome Ritz1.
Abstract
PD-1 expression marks activated T cells susceptible to PD-1-mediated inhibition but not whether a PD-1-mediated signal is being delivered. Molecular predictors of response to PD-1 immune checkpoint blockade (ICB) are needed. We describe a monoclonal antibody (mAb) that detects PD-1 signaling through the detection of phosphorylation of the immunotyrosine switch motif (ITSM) in the intracellular tail of mouse and human PD-1 (phospho-PD-1). We showed PD-1+ tumor-infiltrating lymphocytes (TILs) in MC38 murine tumors had high phosphorylated PD-1, particularly in PD-1+TIM-3+ TILs. Upon PD-1 blockade, PD-1 phosphorylation was decreased in CD8+ TILs. Phospho-PD-1 increased in T cells from healthy human donors after PD-1 engagement and decreased in patients with Hodgkin lymphoma following ICB. These data demonstrate that phosphorylation of the ITSM motif of PD-1 marks dysfunctional T cells that may be rescued with PD-1 blockade. Detection of phospho-PD-1 in TILs is a potential biomarker for PD-1 immunotherapy responses. ©2021 The Authors; Published by the American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34635486 PMCID: PMC8642283 DOI: 10.1158/2326-6066.CIR-21-0493
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 12.020